EGFR and non-small cell lung carcinoma: The discovery and development of therapeutics targeting epidermal growth factor receptor (EGFR), namely tyrosine kinase inhibitors (TKIs), in the past decade was an important clinical advance in non–small cell lung cancer (NSCLC) treatment [3, 4].